Stock Events

Stock Events

Entrada Therapeutics 

$12.21
0
+$0+0% Today

Statistics

Day High
12.21
Day Low
12.21
52W High
-
52W Low
-
Volume
5
Avg. Volume
-
Mkt Cap
466.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-1.15
-1.08
-1.01
-0.94
Expected EPS
-1.0191
Actual EPS
N/A

Financials

31.13%Profit Margin
Profitable
2021
2022
2023
2024
421.56MRevenue
131.25MNet Income

Analyst Ratings

$20.00Average Price Target
The highest estimate is 20.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRDA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Entrada's focus on dystrophic diseases and RNA therapeutics.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing directly in the same therapeutic areas as Entrada.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, directly competing with Entrada in the development of novel RNA-based treatments.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, a direct competitor in RNA therapy.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including genetic disorders targeted by Entrada.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines that target rare disorders, competing in the same therapeutic space as Entrada.
Wave Life Sciences
WVE
Mkt Cap1.44B
Wave Life Sciences is a genetic medicines company focused on designing, optimizing, and producing stereopure oligonucleotides, competing in RNA-based therapy development.

About

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Show more...
CEO
ISIN
US29384C1080

Listings

XNAS
US
TRDA
BOATS
BOATS
TRDA.BOATS

0 Comments

Share your thoughts

FAQ

What is Entrada Therapeutics stock price today?▼
The current price of TRDA.BOATS is $12.21 USD — it has increased by +0% in the past 24 hours. Watch Entrada Therapeutics stock price performance more closely on the chart.
What is Entrada Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Entrada Therapeutics stocks are traded under the ticker TRDA.BOATS.
What is Entrada Therapeutics market cap?▼
Today Entrada Therapeutics has the market capitalization of 466.65M
When is the next Entrada Therapeutics earnings date?▼
Entrada Therapeutics is going to release the next earnings report on May 07, 2026.
What were Entrada Therapeutics earnings last quarter?▼
TRDA.BOATS earnings for the last quarter are -0.94 USD per share, whereas the estimation was -1.15 USD resulting in a +18.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Entrada Therapeutics revenue for the last year?▼
Entrada Therapeutics revenue for the last year amounts to 421.56M USD.
What is Entrada Therapeutics net income for the last year?▼
TRDA.BOATS net income for the last year is 131.25M USD.
When did Entrada Therapeutics complete a stock split?▼
Entrada Therapeutics has not had any recent stock splits.